Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients
Launched by SCHERING-PLOUGH · Aug 30, 2001
Trial Information
Current as of November 12, 2025
Completed
Keywords
ClinConnect Summary
Patients receive SCH 56592 oral suspension or fluconazole suspension for 14 days. Patients remain on study for 44 days total and are monitored for safety and efficacy of study treatment.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- You may be eligible for this study if you:
- • Are at least 18 years old.
- • Are HIV-positive.
- • Have thrush (oropharyngeal candidiasis).
- • Agree to practice sexual abstinence or use effective barrier methods of birth control (e.g., condoms).
- • Are able to take study medication and return for clinic visits during the study.
- • Are expected to live for at least 2 months.
- • Exclusion Criteria
- You will not be eligible for this study if you:
- • Have received protease inhibitors for the first time within 30 days prior to study entry.
- • Have received certain medications.
- • Have certain other types of fungal infections.
- • Have certain types of cancer.
- • Have received SCH 56592 within 3 months prior to study entry.
- • Are pregnant or breast-feeding.
- • Cannot take medications by mouth.
- • Are allergic to azole drugs.
- • Have certain medical conditions.
- • Have been in this study before.
About Schering Plough
Schering-Plough, a leading global biopharmaceutical company, is dedicated to the research, development, and commercialization of innovative therapies that address unmet medical needs across a range of therapeutic areas, including oncology, immunology, and infectious diseases. With a commitment to advancing healthcare through scientific excellence, Schering-Plough leverages cutting-edge technologies and collaborative partnerships to bring transformative treatments to patients worldwide. The company's robust pipeline, combined with its focus on patient-centric solutions, underscores its mission to improve health outcomes and enhance the quality of life for individuals facing complex health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Charleston, South Carolina, United States
Miami, Florida, United States
San Antonio, Texas, United States
Camden, New Jersey, United States
San Francisco, California, United States
Berkeley, California, United States
Detroit, Michigan, United States
Washington, District Of Columbia, United States
San Francisco, California, United States
Indianapolis, Indiana, United States
Brooklyn, New York, United States
Jacksonville, Florida, United States
Dallas, Texas, United States
Denver, Colorado, United States
Chicago, Illinois, United States
Jersey City, New Jersey, United States
Philadelphia, Pennsylvania, United States
St Michael, Barbados
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials